Episode 21: Among the topics: Edge-to-edge mitral valve repair - The future treatment of chronic heart failure

ESC TV Today – Your Cardiovascular News

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly.

This episode covers:

Cardiology This Week: A concise summary of recent studies

Edge-to-edge mitral valve repair

The future treatment of chronic heart failure

Mythbusters: Is chocolate healthy for the heart?

Host: Susanna Price

Guests: Carlos Aguiar, Milton Packer and Stephan Windecker

Want to watch that episode? Go to: https://esc365.escardio.org/event/1122

Disclaimer

This programme is supported by Siemens Healthineers in the form of an educational grant.

The scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor.

This programme is intended for health care professionals only and is to be used for educational purposes.

The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.

Declarations of interests

Stephan Achenbach, Nicolle Kraenkel, Milton Packer and Susanna Price have declared to have no potential conflicts of interest to report.

Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede.

Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi, Daiichi Sankyo, Terumo, Medtronic, Chiesi.

Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer- Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.

Stephan Windecker has declared to have potential conflicts of interest to report: payments from Amgen and Medtronic, research funding from Abbott, Amgen, AstraZeneca, Bayer AG, Biotronik, Boston Scientific, Daiichi Sankyo, Edwards Lifesciences, Guerbet AG, Johnson & Johnson, Medtronic, Novartis, Novo Nordisk, Pfizer, Regeneron, Sanofi Adventis, V-Wave, Abiomed, Boehringer-Ingelheim, Bristol Myers Squibb, B.Braun, Cordis Medical, Miracor medical, Pharming Tech, CSL Behring, Farapulse Inc., Fumedica, Idorsia, Inari Medical, MedAlliance.